The mean lorazepam dose administered in the symptom-triggered group was significantly lower than in the fixed tapering dose group ( @ versus @ mg , P < @ ) and for a significantly shorter duration of time ( @ versus @ h , P < @ ) with more significant results for higher initial CIWA-Ar scores .